Get App
Anlon Healthcare IPO is a bookbuilt issue of Rs 121.03 crore. This issue is entirely a fresh issue of 1.33 crore shares with no offer for sale.
The IPO opens for subscription on August 26, 2025, and closes on August 29, 2025. The allotment is expected to be finalized on Monday, September 1, 2025. The price band for the IPO is set at ₹86 to ₹91 per share, and the minimum lot size for an application is 164 shares.
Company Summary
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacture of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
Company Products
- Pharma Intermediates: Cyanoethylbenzoyl nzoic acid, Ketonitrile, and Methyl desloratadine; these serve as a key starting material or as an advanced intermediate for the manufacturing of APIs.
- Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
The company’s product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at the pilot stage, and forty-nine (49) products at the laboratory testing stage/ laboratory scale stage.
Company Strengths
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 181.3 | 128 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| Net Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
| Amount in ₹ Crore | |||
Objectives of IPO
- Funding capital expenditure requirements for the Proposed Expansion
- Full or part repayment and/or prepayment of certain outstanding secured borrowings secured borrowing (term loan)availed by the Company
- Funding the working capital requirements of the Company
- General corporate purposes
Promoters of the company
Punitkumar R. Rasadia, Meet Atulkumar Vachhani, and Mamata Punitkumar Rasadia are the promoters of the company.
IPO Details
| IPO Date | August 26, 2025 to August 29, 2025 |
| Listing Date | September 3, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹86 to ₹91 per share |
| Lot size | 164 shares |
| Total Issue size | 1,33,00,000 shares (aggregating upto ₹121.03 Cr ) |
| Issue type | Bookbuilding IPO |
| Listing at | NSE, BSE |
| Share Holding Pre Issue | 3,98,51,500 shares |
| Share Holding Post Issue | 5,31,51,500 shares |
Lot Allocation Details
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 164 | ₹14,924.00 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012.00 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936.00 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908.00 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832.00 |
Allotment Schedule
| Basis of Allotment | Mon, 1 Sep, 2025 |
| Initiation of Refunds | Tue, 2 Sep, 2025 |
| Credit of Shares to Demat | Tue, 2 Sep, 2025 |
| Tentative Listing Date | Wed, 3 Sep, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 29, 2025 |
IPO Reservation
| Investor Category | Shares Offered |
| QIB Shares Offered | Not less than 75% of the Net Issue |
| Retail Shares Offered | Not more than 10% of the Net Issue |
| NII Shares Offered | Not less than 15% of the Net Issue |
To check allotment, click here
Download NOVO App!
Invest in Zero-commission Direct Mutual funds, IPO, Sovereign Gold bonds, Government bills, and Corporate bonds.
